Enlivex Therapeutics (ENLV) Competitors $1.04 -0.01 (-0.95%) Closing price 03:55 PM EasternExtended Trading$1.02 -0.02 (-1.44%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENLV vs. BMRA, CNTX, CRBU, SGMT, UNCY, ADAG, VXRT, MNOV, XCUR, and ANLShould you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include Biomerica (BMRA), Context Therapeutics (CNTX), Caribou Biosciences (CRBU), Sagimet Biosciences (SGMT), Unicycive Therapeutics (UNCY), Adagene (ADAG), Vaxart (VXRT), MediciNova (MNOV), Exicure (XCUR), and Adlai Nortye (ANL). These companies are all part of the "pharmaceutical products" industry. Enlivex Therapeutics vs. Biomerica Context Therapeutics Caribou Biosciences Sagimet Biosciences Unicycive Therapeutics Adagene Vaxart MediciNova Exicure Adlai Nortye Biomerica (NASDAQ:BMRA) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, community ranking, valuation and earnings. Does the MarketBeat Community believe in BMRA or ENLV? Biomerica received 77 more outperform votes than Enlivex Therapeutics when rated by MarketBeat users. However, 81.08% of users gave Enlivex Therapeutics an outperform vote while only 67.82% of users gave Biomerica an outperform vote. CompanyUnderperformOutperformBiomericaOutperform Votes13767.82% Underperform Votes6532.18% Enlivex TherapeuticsOutperform Votes6081.08% Underperform Votes1418.92% Which has stronger valuation & earnings, BMRA or ENLV? Biomerica has higher revenue and earnings than Enlivex Therapeutics. Biomerica is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomerica$5.68M1.62-$5.98M-$2.32-1.56Enlivex TherapeuticsN/AN/A-$29.07M-$0.73-1.42 Is BMRA or ENLV more profitable? Enlivex Therapeutics has a net margin of 0.00% compared to Biomerica's net margin of -100.52%. Enlivex Therapeutics' return on equity of -67.57% beat Biomerica's return on equity.Company Net Margins Return on Equity Return on Assets Biomerica-100.52% -90.19% -64.54% Enlivex Therapeutics N/A -67.57%-58.45% Do institutionals and insiders believe in BMRA or ENLV? 22.3% of Biomerica shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 15.0% of Biomerica shares are held by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, BMRA or ENLV? Biomerica has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Do analysts rate BMRA or ENLV? Enlivex Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 861.54%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Enlivex Therapeutics is more favorable than Biomerica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomerica 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Does the media favor BMRA or ENLV? In the previous week, Biomerica had 1 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 1 mentions for Biomerica and 0 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 1.89 beat Biomerica's score of 0.96 indicating that Enlivex Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Biomerica Positive Enlivex Therapeutics Very Positive SummaryEnlivex Therapeutics beats Biomerica on 12 of the 18 factors compared between the two stocks. Get Enlivex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENLV vs. The Competition Export to ExcelMetricEnlivex TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.26M$6.84B$5.55B$8.04BDividend YieldN/A2.95%5.09%4.22%P/E Ratio-1.067.4422.6818.83Price / SalesN/A257.63404.28106.72Price / CashN/A65.8538.1834.62Price / Book0.646.576.794.33Net Income-$29.07M$143.14M$3.22B$247.97M7 Day Performance5.64%3.59%2.44%2.71%1 Month Performance2.97%6.00%3.78%3.37%1 Year Performance-35.80%-2.03%17.05%5.80% Enlivex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENLVEnlivex Therapeutics3.3772 of 5 stars$1.04-1.0%$10.00+861.5%-34.8%$22.26MN/A-1.0670Positive NewsBMRABiomerica1.2749 of 5 stars$3.68-4.2%N/A-28.6%$74.95M$5.58M-10.8260CNTXContext Therapeutics1.9395 of 5 stars$0.83-1.1%$6.17+639.4%-37.3%$74.81MN/A-0.927Analyst ForecastAnalyst RevisionNews CoverageCRBUCaribou Biosciences2.3641 of 5 stars$0.80+8.2%$10.33+1,199.3%-78.3%$73.97M$9.99M-0.48100Upcoming EarningsAnalyst RevisionSGMTSagimet Biosciences2.707 of 5 stars$2.39+8.1%$22.40+837.2%-4.4%$73.31M$2M-1.678Gap UpUNCYUnicycive Therapeutics3.7827 of 5 stars$0.61+1.6%$5.50+801.5%-42.7%$73.03M$680,000.00-0.639Short Interest ↓Positive NewsGap UpADAGAdagene2.9754 of 5 stars$1.55+1.3%$8.00+416.1%-32.0%$73.02M$103,204.000.00260Short Interest ↓News CoverageVXRTVaxart1.4747 of 5 stars$0.32-7.5%$3.00+843.1%-38.8%$72.59M$28.70M-0.78120News CoverageMNOVMediciNova1.8662 of 5 stars$1.47+1.4%$9.00+512.2%+14.0%$72.10M$1M-6.3910Upcoming EarningsAnalyst ForecastShort Interest ↓News CoveragePositive NewsXCURExicure2.1975 of 5 stars$11.30+33.9%N/A+1,854.9%$71.39M$500,000.00-5.4650Short Interest ↓Positive NewsGap UpANLAdlai Nortye2.6395 of 5 stars$1.93+0.8%$9.00+367.5%-84.8%$71.03M$5M0.00127Positive News Related Companies and Tools Related Companies BMRA Competitors CNTX Competitors CRBU Competitors SGMT Competitors UNCY Competitors ADAG Competitors VXRT Competitors MNOV Competitors XCUR Competitors ANL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENLV) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
